Liminatus Pharma, Inc.
PublicLiminatus Pharma, Inc. is now publicly traded
The data on this page reflects Liminatus Pharma, Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Warrant Exercise
Jun 18, 2026
Total Funding Raised
$1.86M
Company Overview
Liminatus Pharma, Inc. is a clinical-stage biopharmaceutical company that develops novel immune-modulating cancer therapies, including CD47-blockade antibodies and cancer vaccines.
AI Layer
Application
Keywords
Liminatus Pharma, Inc. Comparables
Compare Liminatus Pharma, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| InnoBation Bio | 86% | |
| Link Cell Therapies | 69% | |
| Ascendo Biotechnology | 59% |
Liminatus Pharma, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Warrant Exercise | Jun 18, 2026 |
Recent news
Latest coverage and updates
- has_valuationAug 24, 2026
Liminatus Pharma, Inc. had valuation of $6.4M on Aug 24th '26.
- partners_withAug 24, 2026
Liminatus Pharma, Inc. partnered with Synex Consulting Ltd. on Aug 24th '26.
Liminatus Pharma, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access